Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display & Cocktail

14P - Comparison of the predictive power of survival of the Royal Marsden Score, the GRIM score and the LIPI score in phase I trial patients

Date

02 Mar 2020

Session

Poster Display & Cocktail

Presenters

Eduardo Castanon Alvarez

Citation

Annals of Oncology (2020) 31 (suppl_1): S1-S7. 10.1016/annonc/annonc86

Authors

E. Castanon Alvarez1, C. Vidal2, L. Resano2, A. Sánchez3, M. Rodriguez4, D. Salas4, M. Fernandez de Sanmamed4, J.M. López Picazo4, L. Sanchez1, J. Espinos1, I. Melero5, A. Gonzalez1, M. Ponz-Sarvisé1

Author affiliations

  • 1 Department of Oncology, Clinica Universidad de Navarra, Madrid, 28027 - Madrid/ES
  • 2 Clinical Trials Unit, Clinica Universidad de Navarra, 31008 - Pamplona/ES
  • 3 Interdisciplinar Teragnosis And Radiosomics Group, University of Navarra, 28027 - Madrid/ES
  • 4 Department of Oncology, Clinica Universidad de Navarra, Pamplona, 31008 - Pamplona/ES
  • 5 Department of Immunology, Clinica Universidad de Navarra, Pamplona, 31008 - Pamplona/ES
More

Resources

Abstract 14P

Immunotherapy has changed clinical practise. Patient enrolment in immunotherapy phase I trials is still crucial. Therefore, new tests have been developed (GRIM score and LIPI score), challenging the classical ones designed for targeted therapy such as Royal Marsden Score (RMS). Although they include different variables, here we perform a comparison, aimed at identifying if there are differences in terms of their predictive power of survival.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings